Margarida Maia, PhD,  science writer—

Cyrus Biotechnology has selected CYR212 as its clinical development candidate for myasthenia gravis (MG) and other autoimmune diseases driven by immunoglobulin G (IgG) self-reactive antibodies, the company announced in a press release. According to the U.S.-based biotech, CYR212’s profile — as seen in preclinical data culled from…

Many adults with myasthenia gravis (MG) need intensive treatment in the first year after diagnosis, with younger patients and women facing a higher risk of death as the disease progresses, a study found. The researchers said the results point to a need for better treatment options. The study, “…

The healthcare costs of myasthenia gravis (MG) are high, according to a study from Denmark, Finland, and Sweden, and even higher for women and patients with very severe symptoms or coexisting conditions such as mental health problems or severe infections. A large portion of direct costs in all three…

Johnson & Johnson’s nipocalimab appears to be safe and to ease symptoms of generalized myasthenia gravis (gMG) in adolescents with antibodies against the acetylcholine receptor, the most common type of MG-causing antibody, according to six-month data from an open-label clinical trial. The Phase 2/3 Vibrance-MG study…

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase), an approved therapy for generalized myasthenia gravis (gMG) that’s injected under the skin, or subcutaneously, appears to be as effective as the intravenous treatment Vyvgart (efgartigimod alfa) at reducing IgG antibodies, including those that cause the disease. That’s according to data…

Soliris (eculizumab) effectively eased symptoms and reduced the need for other medications in adults with myasthenia gravis (MG) in a clinical practice setting, according to two-year data from an observational study called ELEVATE. Findings were reported in the study “United States clinical practice experience with eculizumab in…

Harbour BioMed has submitted a new, revised version of a biologics license application (BLA) to China’s regulatory agency requesting the approval of batoclimab (HBM9161) to treat generalized myasthenia gravis (MG). The original application was accepted for review last year by China’s National Medical Products Administration (NMPA). The…

Patients who received Vyvgart (efgartigimod alfa) as part of an expanded access program required more frequent dosing to treat generalized myasthenia gravis (gMG) than what was used during clinical testing, according to a small study in the Netherlands. Study findings also showed that more than half of the…

Butyric acid from gut bacteria, or supplementation with its salt form butyrate, could become potential treatments for myasthenia gravis (MG) by working to restore the function of immune cells that limit the production of disease-causing antibodies. That’s according to the findings of a new study in human cells and…

Many of the adults with generalized myasthenia gravis (gMG) who took part in ADAPT, a Phase 3 clinical study of Vyvgart (efgartigimod), and its open-label extension, ADAPT+, experienced minimal or no symptoms and a quality of life closer to that of healthy adults. While Vyvgart is approved to…